Search Results 1381-1390 of 19452 for Hemoglobin

1. Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim 3) - Mayo Clinic

   Hemoglobin <9 g/dL; Patients with severe liver disease (AST > 3x normal, alkaline phosphatase or bilirubin > 2x normal); Serum sodium of < 125 mEq/dL or > 150 ...

2. Tai Chi on Colorectal Cancer Survivors With Fatigue - Mayo Clinic

   Hemoglobin < 9.0 g/dL; Unwilling to comply with scheduled visits and class participation, defined as attendance in 6 or more classes. Participating Mayo ...

3. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

   Bone marrow: platelets ≥75 x 109/L, absolute neutrophil count (ANC) ≥1.5 x 109/L, hemoglobin ≥10 g/dL. (Platelets ≥50 x 109/L, ANC ≥1.0 x 109/L, hemoglobin ...

4. Mayo researchers develop new genetics-based prognostic tool for myelodysplastic syndrome

   “In addition to accommodating genetic information, it offers more user-friendly cytogenetic risk stratification, accounts for gender differences in hemoglobin ...

5. A Study to Evaluate the Effectiveness and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - Mayo Clinic

   Hemoglobin | ≤ 9.0 g/dL (transfusion allowed with 2-week washout period);; ANC | ≤ 1.5 × 109/L. Hepatic. ALT | > 2.5 × ULN (> 5 × ULN if related to ...

6. Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma - Mayo Clinic

   Hemoglobin (Hgb) ≥ 8 g/dL. Potassium within normal limits; Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and Alanine ...

7. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

   Hemoglobin ≥ 9 g/dL. Have no clinically significant abnormalities on urinalysis. Have acceptable coagulation status: Prothrombin time (PT) within 1.5 ...

8. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] ≥ 9.0 g/dl is acceptable) (within 14 days prior to ...

9. A Study of GDC-0449 and Erlotinib Hydrochloride, with or without Gemcitabine Hydrochloride for Treating Patients with Metastatic Pancreatic Cancer or Solid Tumors that cannot be Removed by Surgery - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL; International Normalized Ratio (INR) within normal limits (for patients treated at the MTD); Ability to provide informed consent ...

10. Regorafenib in Metastatic Colorectal Cancer - Mayo Clinic

    Platelet count ≥ 100,000, hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1,500. Blood transfusion to meet the inclusion criteria not be allowed ...